Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.
Suresh
S
S
Schilling
S
S
Dakin
C
C
Harris
M-A
MA
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D001315:Australia / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D006801:Humans; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control*; D012306:Risk
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab